Stock Alert: OpGen Shares Soar 72% In Pre-Market

OpGen Inc. (OPGN) shares are soaring over 70% in pre-market today, after the company announced that Curetis started offering a CE-IVD certified real-time PCR test kit for SARS-CoV2 (also known as 2019-nCov), the causal pathogen of Corona Virus Disease 2019 (Covid-19).

The test kit was developed and is manufactured by Curetis' strategic partner BGI (Shenzhen, China) and was cleared by Chinese authorities in January 2020. In compliance with European regulations for in-vitro-diagnostics (IVD) tests, the test kit was CE-IVD certified on February 28, 2020.

On Sept. 4, 2019, OpGen and Curetis entered into a definitive agreement to combine businesses to create a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiology.

OPGN has been trading between $0.92 and $25.38 in the past one year, and closed Friday's trade at $2.01, up 10 cents or 5.24%. The stock is currently trading at $3.46, up $1.45 or 72.14% in the pre-market trading session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT